Schimke immunwsseous dysplasia (SIOD) is a rare autosomal recessive osteochondrodysplasia that presents in infancy or childhood. It is characterized by spondyloepiphyseal dysplasia, growth failure, proteinuria progressing to renal failure, characteristic facial features, lymphopenia with immunodeficiency, occasional pancytopenia, cerebral vascular disease, and autoimmune dysfunction. It is associated with significant early morbidity and mortality with death during childhood in classic cases. The underlying molecular etiology is unknown. There is rr, effective curative treatment. While dialysis and renal transplantation have successfully managed the renal disease, much of the disease related morbidity and early mortality is due to cell-mediated immunodeficiency that has been refractory to medical therapy. Given the utility of bone marrow transplant (BMT) in the treatment of other immunodeficiency and hypoplastic bone marrow states, we successfully utilized BMT for the management of SIOD in a boy who presented with severe marrow hypoplasia and immunodeficiency. BMT had not been reported for the management of SIOD. The patient was a six-year-old boy wfio initially presented in infancy with short stature and gastrointestinal problems. He later displayed classic features of SIOD, includ~ng progressive renal disease. His renal dtsease progressed after BMT. He subsequently underwent a related donor renal transplant 18 months after BMT. At 20 months after BMT and 2 months following renal transplant he demonstrates sign~ficantly improved immune function, reconstitution of all marrow derived cell lineages, good renal function, and, importantly, an improved sense of overall well being with increased appetite and activity. He had no adverse chronic neurological sequelae. Based on the excdlent outcome of our patient to date, we predict that, until better targeted therapies are developed, bone marrow transplantation In add~tion to renal transplantatton may provide the most effective therapy currently available for severe SIOD, decreasing the morbid~ty in, and increasing the lifespan of, ch~ldren with this disorder.
A close relationship to Smith-Lemli-Opitz (RSH) patients positively correlates with an increased incidence of high cholesterol, late-onset diabetes, and infertility; and negatively correlates with alcoholism.
A.F. Poss, 1.E. Metherall, and J.M. Opitz. Univ. of Utah, Salt Lake City, UT.
Several valuable sets of data came out of the Second International Scientific Symposium on Smith-Lemlt-Opitz/RSH Syndrome held in Salt Lake City in July 1999. One part of this is our study of comorbidity factors in heterozygotes from 23 collected pedigrees (over 450 individuals described). We first asked whether the relatively high frequency of SLO/RSH (1/10,000 births) in the population might be due in part to a fitness advantage in the heterozygotes. Our initial hypothesis was based on the idea that heterozygotes produce less cholesterol, thus protecting them from lipotropic disease. Surprisingly, our data indicated an increased incidence of high cholesterol and late-onset diabetes in close relatives of patients. Therefore, there appeared to be no protective effect offered by the altered cholesterol metabolic pathway in SLO/RSH heterozygotes, but instead a trend toward increases in lipid-related disease. We also found that presumed SLO/RSH heterozygotes exhibtt previously unrecogntzed trends such as a positive correlation with inferttlity and a negatlve correlation with alcoholism. These data provlde new insight for our understanding of the potential role of 7-DHC mutation carrier status, and for future interpretation of similar findings in familtes suspected for SLO/RSH. Smith-Magenis syndrome (SMS) is a multiple congenital anomalies, mental retardation syndrome associated with a hemizygous deletion of chromosome band 17~11.2. The majority of patients have the same sized deletion; however, patients with smaller and larger deletions have been described. Characteristic features of SMS include a significant sleep disturbance. Urinary excretion of 6-sulphatoxymelatonin (aMT6s)-the major hepatic metabolite of melatonin-in conjunction with 24-hour sleep studies in 28 SMS patients reveal an aberrant diurnal rhythm of aMT6s and abnormalities in quality and quantity of nocturnal and daytime sleep. These data demonstrate a disturbed circadian rhythm of melatonin and objectively document the disturbed sleep pattern in Smith-Magenis syndrome. Our findings suggest that these abnormalities may be secondary to aberrations in the production, secretion, distribution, or metabolism of melatonin. One candidate, the gene for subunit 3 (COPS3) of the COP9 signalosome is conserved from plants to humans. In plants COP9 transduces light signals into gene expression, and in humans COPS3 maps within the SMS common deletion interval. We are investigating the hypothesis that C O P S 3 haploinsufficiency may be responsible for the abnormal melatonin circadian rhythm in SMS.
